{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T08:33:41Z","timestamp":1770453221344,"version":"3.49.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.rce.2018.01.004","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T23:36:26Z","timestamp":1518478586000},"page":"244-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tratamiento y prevenci\u00f3n de la enfermedad neumoc\u00f3cica invasiva"],"prefix":"10.1016","volume":"218","author":[{"given":"A.R.","family":"Dom\u00ednguez-Alegr\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Pintado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Barbolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rce.2018.01.004_bib0400","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report: Emerging Infections Program Network. Streptococcus pneumoniae, 2015 [consultado 8 Ago 2017]. CDC; 2016. Disponible en: https:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/spneu15.html"},{"key":"10.1016\/j.rce.2018.01.004_bib0405","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12879-016-1648-2","article-title":"Epidemiology of invasive pneumococcal infections: Manifestations, incidence and case fatality rate correlated to age, gender and risk factors","volume":"16","author":"Backhaus","year":"2016","journal-title":"BMC Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0410","article-title":"Caracter\u00edsticas cl\u00ednicas y microbiol\u00f3gicas de las manifestaciones inusuales de la enfermedad invasiva neumoc\u00f3cica","author":"Sousa","year":"2017","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.rce.2018.01.004_bib0415","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.medmal.2012.04.003","article-title":"Pneumococcal infections and adult with risk factors","volume":"42","author":"Chidiac","year":"2012","journal-title":"Med Mal Infect."},{"key":"10.1016\/j.rce.2018.01.004_bib0420","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","article-title":"Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease","volume":"70","author":"Torres","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.rce.2018.01.004_bib0425","unstructured":"European Centre for Disease Prevention and Control. Invasive pneumococcal disease - Annual epidemiological report 2016 [2014 data]. [consultado 8 Ago 2017]. ECDC; 2016. Disponible en: https:\/\/ecdc.europa.eu\/en\/publications-data\/invasive-pneumococcal-disease-annual-epidemiological-report-2016-2014-data"},{"key":"10.1016\/j.rce.2018.01.004_bib0430","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jinf.2016.01.011","article-title":"Declining mortality from adult pneumococcal infections linked to children's vaccination","volume":"72","author":"Grau","year":"2016","journal-title":"J Infect."},{"key":"10.1016\/j.rce.2018.01.004_bib0435","first-page":"57","article-title":"The changing epidemiology of invasive pneumococcal disease after the introduction of pneumococcal conjugate vaccine, Rhode Island, 1997-2016","volume":"100","author":"Gosciminski","year":"2017","journal-title":"R I Med J (2013)"},{"key":"10.1016\/j.rce.2018.01.004_bib0440","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1016\/j.vaccine.2015.08.009","article-title":"Secular trends (1990-2013) in serotypes and associated non-susceptibility of S. pneumoniae isolates causing invasive disease in the pre-\/post-era of pneumococcal conjugate vaccines in Spanish regions without universal paediatric pneumococcal vaccination","volume":"33","author":"Fenoll","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.rce.2018.01.004_bib0445","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jpeds.2015.12.031","article-title":"Bacteremic pneumonia before and after withdrawal of 13-valent pneumococcal conjugate vaccine from a public vaccination program in Spain: A case-control study","volume":"171","author":"Tagarro","year":"2016","journal-title":"J Pediatr."},{"key":"10.1016\/j.rce.2018.01.004_bib0450","first-page":"155","article-title":"Bacteriemia neumoc\u00f3cica en pacientes adultos de un hospital de Madrid: serotipos y sensibilidad antibi\u00f3tica","volume":"25","author":"Correa","year":"2012","journal-title":"Rev Esp Quimioter."},{"key":"10.1016\/j.rce.2018.01.004_bib0455","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1128\/JCM.01454-08","article-title":"Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007","volume":"47","author":"Fenoll","year":"2009","journal-title":"J Clin Microbiol."},{"key":"10.1016\/j.rce.2018.01.004_bib0460","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1017\/S0950268817001194","article-title":"The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has there been a herd effect?","volume":"145","author":"Corcoran","year":"2017","journal-title":"Epidemiol Infect."},{"key":"10.1016\/j.rce.2018.01.004_bib0465","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/cid\/cix685","article-title":"Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations","volume":"65","author":"Naucler","year":"2017","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0795","doi-asserted-by":"crossref","first-page":"100.e1","DOI":"10.1016\/j.amjmed.2017.06.039","article-title":"Effect of age on the manifestations and outcomes of invasive pneumococcal disease in adults","volume":"131","author":"Marrie","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.rce.2018.01.004_bib0475","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1469-0691.2012.03937.x","article-title":"Understanding the burden of pneumococcal disease in adults","volume":"18","author":"Blasi","year":"2012","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.rce.2018.01.004_bib0480","doi-asserted-by":"crossref","first-page":"34S","DOI":"10.1016\/S0002-9343(99)00098-4","article-title":"Bacteremic pneumococcal pneumonia in one American City: A 20-year longitudinal study, 1978-1997","volume":"107","author":"Mufson","year":"1999","journal-title":"Am J Med."},{"key":"10.1016\/j.rce.2018.01.004_bib0485","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1183\/09031936.00034415","article-title":"The problem of early mortality in pneumococcal pneumonia: A study of risk factors","volume":"46","author":"Burgos","year":"2015","journal-title":"Eur Respir J."},{"key":"10.1016\/j.rce.2018.01.004_bib0490","doi-asserted-by":"crossref","first-page":"e5179","DOI":"10.1097\/MD.0000000000005179","article-title":"Prognostic factors associated with mortality and major in-hospital complications in patients with bacteremic pneumococcal pneumonia: Population-based study","volume":"95","author":"Beatty","year":"2016","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.rce.2018.01.004_bib0495","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MD.0b013e31821a5a76","article-title":"Factors predicting mortality in invasive pneumococcal disease in adults in Alberta","volume":"90","author":"Marrie","year":"2011","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.rce.2018.01.004_bib0500","doi-asserted-by":"crossref","first-page":"e1000081","DOI":"10.1371\/journal.pmed.1000081","article-title":"Pneumococcal serotypes and mortality following invasive pneumococcal disease: A population-based cohort study","volume":"6","author":"Harboe","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.rce.2018.01.004_bib0505","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1098\/rsob.150269","article-title":"Streptococcus pneumoniae capsule determines disease severity in experimental pneumococcal meningitis","volume":"6","author":"Hathaway","year":"2016","journal-title":"Open Biol."},{"key":"10.1016\/j.rce.2018.01.004_bib0510","doi-asserted-by":"crossref","first-page":"e0182436","DOI":"10.1371\/journal.pone.0182436","article-title":"Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia","volume":"12","author":"Cill\u00f3niz","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.rce.2018.01.004_bib0515","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s15010-015-0801-y","article-title":"Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults","volume":"43","author":"Vila-Corcoles","year":"2015","journal-title":"Infection."},{"key":"10.1016\/j.rce.2018.01.004_bib0520","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1086\/377534","article-title":"An international prospective study of pneumococcal bacteremia: Correlation with in vitro resistance, antibiotics administered, and clinical outcome","volume":"37","author":"Yu","year":"2003","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0525","doi-asserted-by":"crossref","first-page":"426","DOI":"10.47102\/annals-acadmedsg.V34N7p426","article-title":"Early predictors of mortality in pneumococcal bacteraemia","volume":"34","author":"Imran","year":"2005","journal-title":"Ann Acad Med Singapore."},{"key":"10.1016\/j.rce.2018.01.004_bib0530","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ajem.2015.10.025","article-title":"Prognostic factors of Streptococcus pneumoniae infection in adults","volume":"34","author":"Hifumi","year":"2016","journal-title":"Am J Emerg Med."},{"key":"10.1016\/j.rce.2018.01.004_bib0535","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s15010-015-0837-z","article-title":"Bacteremic pneumococcal pneumonia: Clinical outcomes and preliminary results of inflammatory response","volume":"43","author":"Bordon","year":"2015","journal-title":"Infection."},{"key":"10.1016\/j.rce.2018.01.004_bib0540","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM197810052991402","article-title":"Emergence of multiply resistant pneumococci","volume":"299","author":"Jacobs","year":"1978","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2018.01.004_bib0545","first-page":"1353","article-title":"Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae--United States, 2006-2007","volume":"57","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.rce.2018.01.004_bib0550","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1086\/598975","article-title":"Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: Coping with antimicrobial susceptibility in an era of resistance","volume":"48","author":"Weinstein","year":"2009","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0555","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1086\/500140","article-title":"The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: A systematic review and meta-analysis","volume":"42","author":"Tleyjeh","year":"2006","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0560","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/322623","article-title":"Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance","volume":"33","author":"Moroney","year":"2001","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0565","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJM199508243330802","article-title":"Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain","volume":"333","author":"Pallares","year":"1995","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2018.01.004_bib0570","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MCP.0000000000000262","article-title":"What is the clinical relevance of drug-resistant pneumococcus?","volume":"22","author":"Cill\u00f3niz","year":"2016","journal-title":"Curr Opin Pulm Med."},{"key":"10.1016\/j.rce.2018.01.004_bib0575","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM200202213460820","article-title":"Emergence of macrolide resistance during treatment of pneumococcal pneumonia","volume":"346","author":"Musher","year":"2002","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2018.01.004_bib0580","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.idc.2012.11.013","article-title":"What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide nonotherapy be used for mild pneumonia?)","volume":"27","author":"Low","year":"2013","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.rce.2018.01.004_bib0585","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1128\/AAC.02669-13","article-title":"Fluoroquinolone-resistant pneumococci: Dynamics of serotypes and clones in Spain in 2012 compared with those from 2002 and 2006","volume":"58","author":"Domenech","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.rce.2018.01.004_bib0590","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMoa012122","article-title":"Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia","volume":"346","author":"Davidson","year":"2002","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2018.01.004_bib0595","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1128\/AAC.05658-11","article-title":"Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: An Asian Network for Surveillance of Resistant Pathogens (ANSORP) study","volume":"56","author":"Kim","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.rce.2018.01.004_bib0600","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1128\/JCM.01642-12","article-title":"Bacteremic pneumonia caused by extensively drug-resistant Streptococcus pneumoniae","volume":"50","author":"Kang","year":"2012","journal-title":"J Clin Microbiol."},{"key":"10.1016\/j.rce.2018.01.004_bib0605","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/429242","article-title":"Predicting antimicrobial resistance in invasive pneumococcal infections","volume":"40","author":"Vanderkooi","year":"2005","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0610","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/archinte.161.15.1837","article-title":"Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia","volume":"161","author":"Waterer","year":"2001","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.rce.2018.01.004_bib0615","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/367541","article-title":"Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia","volume":"36","author":"Mart\u00ednez","year":"2003","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0620","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1164\/rccm.200311-1578OC","article-title":"Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia","volume":"170","author":"Baddour","year":"2004","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.rce.2018.01.004_bib0625","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1378\/chest.06-1426","article-title":"Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones","volume":"131","author":"Metersky","year":"2007","journal-title":"Chest."},{"key":"10.1016\/j.rce.2018.01.004_bib0630","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","article-title":"Macrolides and mortality in critically ill patients with community-acquired pneumonia: A systematic review and meta-analysis","volume":"42","author":"Sligl","year":"2014","journal-title":"Crit Care Med."},{"key":"10.1016\/j.rce.2018.01.004_bib0635","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s10096-005-0018-6","article-title":"Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis","volume":"24","author":"Harbarth","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0640","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10096-006-0183-2","article-title":"Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia","volume":"25","author":"Dwyer","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0645","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1183\/09031936.06.00126004","article-title":"Impact of initial antibiotic choice on mortality from pneumococcal pneumonia","volume":"27","author":"Aspa","year":"2006","journal-title":"Eur Respir J."},{"key":"10.1016\/j.rce.2018.01.004_bib0650","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10096-007-0307-3","article-title":"Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia","volume":"26","author":"Chokshi","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0655","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1378\/chest.128.2.940","article-title":"The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia","volume":"128","author":"Weiss","year":"2005","journal-title":"Chest."},{"key":"10.1016\/j.rce.2018.01.004_bib0660","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jinf.2011.06.009","article-title":"Immunomodulatory agents in the treatment of community-acquired pneumonia: A systematic review","volume":"63","author":"Corrales-Medina","year":"2011","journal-title":"J Infect."},{"key":"10.1016\/j.rce.2018.01.004_bib0665","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1378\/chest.11-1908","article-title":"Macrolide antibiotics and survival in patients with acute lung injury","volume":"141","author":"Walkey","year":"2012","journal-title":"Chest."},{"key":"10.1016\/j.rce.2018.01.004_bib0670","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1086\/428056","article-title":"Challenges in the management of community-acquired pneumonia: The role of quinolones and moxifloxacin","volume":"41","author":"Niederman","year":"2005","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0675","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.arbres.2010.06.014","article-title":"Neumon\u00eda adquirida en la comunidad. Nueva normativa de la Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR)","volume":"46","author":"Men\u00e9ndez","year":"2010","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.rce.2018.01.004_bib0680","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rce.2018.01.004_bib0685","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0690","unstructured":"Tacconelli E, Magrini N. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics [consultado 17 Ago 2017). WHO. 27 de febrero de 2017. Disponible en: http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1"},{"key":"10.1016\/j.rce.2018.01.004_bib0695","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3949\/ccjm.82a.14105","article-title":"Ceftaroline fosamil: A super-cephalosporin?","volume":"82","author":"Ghamrawi","year":"2015","journal-title":"Cleve Clin J Med."},{"issue":"Suppl 2","key":"10.1016\/j.rce.2018.01.004_bib0700","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0213-005X(14)70153-3","article-title":"Farmacocin\u00e9tica y farmacodinamia de ceftarolina","volume":"32","author":"Grau","year":"2014","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.rce.2018.01.004_bib0705","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/mdr.2016.0258","article-title":"Ceftaroline activity against multidrug-resistant Streptococcus pneumoniae from U. S. medical centers (2014) and molecular characterization of a single ceftaroline nonsusceptible isolate","volume":"23","author":"Pfaller","year":"2017","journal-title":"Microb Drug Resist."},{"key":"10.1016\/j.rce.2018.01.004_bib0710","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.diagmicrobio.2012.12.002","article-title":"Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: Insights from two randomized trials","volume":"75","author":"Shorr","year":"2013","journal-title":"Diagn Microbiol Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0715","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.rce.2018.01.004_bib0720","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0725","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2146\/ajhp130482","article-title":"Tedizolid: A new oxazolidinone antimicrobial","volume":"71","author":"Kisgen","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.rce.2018.01.004_bib0730","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s10096-016-2744-3","article-title":"In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China","volume":"35","author":"Biedenbach","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0735","doi-asserted-by":"crossref","first-page":"e01957-16","DOI":"10.1128\/AAC.01957-16","article-title":"Comparative in vivo efficacies of tedizolid in neutropenic versus immunocompetent murine Streptococcus pneumoniae lung infection models","volume":"61","author":"Abdelraouf","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.rce.2018.01.004_bib0740","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide antibacterial agents in gram-positive nfections: A comparative review","volume":"75","author":"Van Bambeke","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.rce.2018.01.004_bib0745","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/QCO.0000000000000246","article-title":"Pneumococcal vaccination","volume":"29","author":"Cill\u00f3niz","year":"2016","journal-title":"Curr Opin Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0750","first-page":"142","article-title":"Consenso sobre la vacunaci\u00f3n anti-neumoc\u00f3cica en el adulto por riesgo de edad y patolog\u00eda de base. Actualizaci\u00f3n 2017","volume":"30","author":"Gonz\u00e1lez-Romo","year":"2017","journal-title":"Rev Esp Quimioter."},{"key":"10.1016\/j.rce.2018.01.004_bib0755","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00006454-198601000-00009","article-title":"First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants","volume":"5","author":"Koskela","year":"1986","journal-title":"Pediatr Infect Dis."},{"key":"10.1016\/j.rce.2018.01.004_bib0760","first-page":"201","article-title":"Polysaccharide vaccine for prevention of Haemophilus influenzae type b disease","volume":"34","year":"1985","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.rce.2018.01.004_bib0765","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1128\/CVI.00721-15","article-title":"Pneumococcal vaccination in high-risk individuals: Are we doing it right?","volume":"23","author":"Papadatou","year":"2016","journal-title":"Clin Vaccine Immunol."},{"key":"10.1016\/j.rce.2018.01.004_bib0770","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.medcli.2015.09.015","article-title":"Neumon\u00eda neumoc\u00f3cica en adultos mayores de 60 a\u00f1os: incidencia, mortalidad y prevenci\u00f3n","volume":"146","author":"Vila-Corcoles","year":"2016","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.rce.2018.01.004_bib0775","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1016\/j.vaccine.2012.09.019","article-title":"Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales","volume":"30","author":"Andrews","year":"2012","journal-title":"Vaccine."},{"key":"10.1016\/j.rce.2018.01.004_bib0780","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1016\/j.vaccine.2013.05.010","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.rce.2018.01.004_bib0785","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine."},{"key":"10.1016\/j.rce.2018.01.004_bib0790","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.vaccine.2014.02.002","article-title":"Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-na\u00efve adults 60-64 years of age","volume":"32","author":"Greenberg","year":"2014","journal-title":"Vaccine"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256518300237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256518300237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:06:50Z","timestamp":1751396810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014256518300237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0014256518300237"],"URL":"https:\/\/doi.org\/10.1016\/j.rce.2018.01.004","relation":{},"ISSN":["0014-2565"],"issn-type":[{"value":"0014-2565","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento y prevenci\u00f3n de la enfermedad neumoc\u00f3cica invasiva","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2018.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights reserved.","name":"copyright","label":"Copyright"}]}}